Table 3 Temporal overview of patient care in survivors and non-survivors in the haemoadsorption group. The p values indicate the statistical impact on survival, eventually when haemoadsorption is deployed within a certain time frame upon ICU admission.

From: Critical risks of haemoadsorption for COVID-19 patients and directions for future evaluations: a nationwide propensity score matched cohort study

 

Survivors (n = 261)

Non-survivors (n = 768)

 

Patient care timings, median (IQR) in days

p

ICU admission to deployment of haemoadsorption

5 (1–13)

7 (2–14)

0.0104

Hospitalisation to deployment of haemoadsorption

7 (2–15)

9 (3–17)

0.0095

ICU admission to deployment of haemoadsorption

 

≤ 24 h

66

(25.29%)

136

(17.71%)

0.8348

> 24 h – ≤ 48 h

19

(7.28%)

52

(6.77%)

0.5493

> 48 h – ≤ 72 h

13

(4.98%)

41

(5.34%)

0.4317

> 72 h – ≤ 87 h

10

(3.83%)

24

(3.13%)

0.6197

> 87 h

138

(52.87%)

491

(63.93%)

0.6773

Total*

246

(94.25%)

744

(96.88%)

 
  1. Data are n (%), unless otherwise stated. The time refers to the period from admission to the treatment clinic to the start of haemoadsorption therapy and does not take into account possible earlier treatment in the event of a transfer. *timing data was not available for all patients. ICU, intensive care unit; IQR, interquartile range; OR, odds ratio; CI, confidence interval.
Back to article page